mRNA expressions of androgen receptor and its variants in matched hormone-sensitive and castration-resistant prostate cancer

References

• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends – An update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.
   PubMed Web of Science ®Google Scholar
• Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532–2542.
   PubMed Web of Science ®Google Scholar
• Uo T, Sprenger C. Androgen receptor variants and castration-resistant prostate cancer: looking back and looking forward. Eur Urol. 2018;73(5):724–726.
   PubMed Web of Science ®Google Scholar
• Chandrasekar T, Yang JC, Gao AC, et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365–380.
   PubMed Web of Science ®Google Scholar
• Luo J, Attard G, Balk SP, et al. Role of androgen receptor variants in prostate cancer: report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018;73(5):715–723.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–1038.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–252.
   PubMed Web of Science ®Google Scholar
• Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317–325.
   PubMed Web of Science ®Google Scholar
• Kwon MJ, Sung CO, Kang SY, et al. Differential expression of extracellular matrix-related genes in rare variants of meningioma. Human Pathol. 2013;44(2):260–268.
   PubMed Web of Science ®Google Scholar
• Wang H, Horbinski C, Wu H, et al. NanoStringDiff: a novel statistical method for differential expression analysis based on NanoString nCounter data. Nucleic Acids Res. 2016;44(20):e151.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017.
   Google Scholar
• Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149–2156.
   PubMed Web of Science ®Google Scholar
• Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2(11):14411441–14411449.
   Web of Science ®Google Scholar
• Sharp A, Coleman I, Yuan W, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2018;129(1):192–208.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–1025.
   PubMed Web of Science ®Google Scholar
• Chen X, Bernemann C, Tolkach Y, et al. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. Urol Oncol. 2018;36(4):161 e19–161 e30.
   Web of Science ®Google Scholar
• Li H, Wang Z, Xiao W, et al. Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients. Mod Pathol. 2018;31(1):198–208.
   PubMed Web of Science ®Google Scholar
• Kallio HML, Hieta R, Latonen L, et al. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. Br J Cancer. 2018;119(3):347–356.
   PubMed Web of Science ®Google Scholar
• Saylor PJ, Lee RJ, Arora KS, et al. Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer. Clin Cancer Res. 2017;23(2):363–369.
   PubMed Web of Science ®Google Scholar
• Hornberg E, Ylitalo EB, Crnalic S, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One. 2011;6(4):e19059.
   PubMed Web of Science ®Google Scholar
• Takayama KI. Splicing factors have an essential role in prostate cancer progression and androgen receptor signaling. Biomolecules. 2019;9(4):131.
   PubMed Web of Science ®Google Scholar
• Yu Z, Chen S, Sowalsky AG, et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014;20(6):1590–1600.
   PubMed Web of Science ®Google Scholar
• Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–1228.
   PubMed Web of Science ®Google Scholar
• Welti J, Rodrigues DN, Sharp A, et al. Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol. 2016;70(4):599–608.
   PubMed Web of Science ®Google Scholar
• Sheridan TB, Carter HB, Wang W, et al. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol. 2008;179(3):901–904.
   PubMed Web of Science ®Google Scholar
• Small EJ, Huang J, Youngren J, et al. Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). J Clin Oncol. 2015;33(15_suppl):5003–5003.
   Web of Science ®Google Scholar
• Antonarakis ES, Armstrong AJ, Dehm SM, et al. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016;19(3):231–241.
   PubMed Web of Science ®Google Scholar